Profound Growth Failure in Peripubertal Adolescents presenting with Severe Acquired Autoimmune Hypothyroidism

Sze May Ng* and Louise J Apperley
Department of Paediatrics, Southport and Ormskirk NHS Trust, Ormskirk, United Kingdom

Article Info

*Corresponding author:
Sze May Ng
Department of Paediatrics
Southport and Ormskirk NHS Trust
Ormskirk, United Kingdom
Tel: 01695 656163
Fax: 01695 656282
E-mail: may.ng@nhs.net

Received: May 29, 2019
Accepted: June 20, 2019
Published: June 27, 2019


Copyright: © 2019 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published by Madridge Publishers

Abstract

Introduction: Optimal thyroid function levels are essential for neurodevelopment, growth and pubertal development. Hypothyroidism is the most common endocrine disorder and is caused by an underactive thyroid gland.

Methods: Four peri-pubertal females were referred to a local paediatric centre with profound short stature. All patients were diagnosed with autoimmune hypothyroidism. This case series reports on the presentation, investigations and management of females with severe autoimmune hypothyroidism and presented with short stature.

Results: All four females were peri-pubertal on presentation to clinic and were found to have poor growth and significant short stature at -3.16 to -4.99 SD. Biochemical results confirmed severe hypothyroidism (TSH>100 and FT4<1) with positive thyroid peroxidase antibodies for all patients. All four patients had normal growth hormone stimulation tests and significantly delayed bone age [mean 3.3 years]. All patients had a thyroid ultrasound, which confirmed thyroiditis. Height SDS improved following thyroid replacement by 0.645 ± 0.515 SD.

Conclusion: It is important to consider hypothyroidism as a cause for poor growth in children and prompt recognition is essential to initiate treatment early, so that adult height is not compromised.

Keywords: Autoimmune; Hypothyroidism; Thyroiditis; Short Stature.

Abbreviations: Pubertal Staging B: Breast Stage; Pubertal Staging P: Pubic Hair Stage; Pubertal Staging A: Axillary Hair Stage; Pubertal Staging M: Menarche Stage; SDS: Standard Deviation Scores; TPO: Thyroid Peroxidase; TSH: Thyroid Stimulating Hormone.

Introduction

Hypothyroidism is the most common endocrine disorder, which is a result of an underactive thyroid gland [1,2]. Most cases are diagnosed by high levels of thyroid stimulating hormone (TSH) and low levels of free T4(FT4) [1,2]. Euthyroid, normal thyroid hormone levels, is essential for optimal neurodevelopment, growth and pubertal development [3,4]. Thyroid hormones are involved in the growth hormone process, especially the production and triggering of insulin-like growth factor 1 [4].

Autoimmune hypothyroidism is the most common type of hypothyroidism in Western Countries. It is mostly characterised by the presence of thyroid autoantibodies [1-3]. The clinical picture of the disorder can vary between individuals.
Autoimmune thyroiditis often occurs during adolescence period, between early and mid-puberty. The condition is predominantly seen in females [2,3,5] with a prevalence of 1-2% [6]. In 1995, Vander pump reported the incidence for autoimmune hypothyroidism as 0.6 and 4.1 per 1000 in males and females retrospectively [7]. These numbers have barely changed over the years as Halawani et al. showed in a systematic review in 2017 that the incidence was 0.8 and 3.5 per 1000 in males and females retrospectively [8].

There are multiple signs and symptoms for hypothyroidism which include lethargy, increased weight, intolerance to cold, constipation and lanugo-like hair [1,3,6]. The presence of goitre usually triggers the patient to seek medical advice and is found to be the most common presentation [2]. Interestingly, one of the most common clinical findings in patients diagnosed with hypothyroidism is slowing growth velocity [2,3,9]. It is a gradual progression and may have been ongoing for years before diagnosis is made [2]. Other associations with hypothyroidism are bone delay and pubertal concerns [3,6,9].

The treatment for hypothyroidism is levothyroxine [1,6]. The thyroid function tests must be monitored closely initially until optimal thyroxine replacement has been achieved. The overall aim for treatment is to maintain a euthyroid picture, both clinically and biochemically [6].

In delayed treatment of hypothyroidism during peri-pubertal growth, even with optimal treatment, studies have reported that catch up growth may not be possible. This is thought to be secondary to skeletal progression following the initiation of thyroxine and, if the treatment is delayed and therefore the child is older, this allows less time for catch up growth to occur [10,11].

The aim of this paper was to evaluate the presentation, investigations and catch up growth following thyroxine treatment.

Method

Four peri-pubertal females presented to a local paediatric centre between September 2014 and December 2018 with severe growth restriction and later diagnosed with autoimmune hypothyroidism. All patients had been seen by their general practitioners prior to being referred to the paediatric endocrinologist for short stature.

Pubertal status was staged according to Odel W [12]. Height and body mass index was expressed as standard deviation scores (SDS) with reference to British standards [13] and bone age was estimated by a consultant radiologist in the Department of Radiology using the RUS (TW2) [14].

Each patient had their TSH, FT4 and Thyroid peroxidase antibodies (TPO) assessed along with growth hormone stimulation tests using glucagon stimulation test as per local protocol. Their thyroid function was then monitored following the initiation of thyroxine replacement. All patients also had wrist X-rays, to determine their bone age, and thyroid scans. The growth of the patients was monitored and plotted onto appropriate growth charts every three to four months.

Results

The main symptom for referral for all patients was short stature. Following a full history and examination, further symptoms were noted such as constipation, cold intolerance and low mood. None of the patients had physical signs of hypothyroidism, for example bradycardia, goitre, pretibial oedema or delay in relaxation of the ankle reflex.

All four patients had TSH levels over 100 mU/L at presentation with undetectable FT4 levels. The positive TPO antibodies along with ultrasound findings of thyroiditis support the diagnosis of autoimmune hypothyroidism. The hormone stimulation tests were normal, which show that the short stature is secondary to hypothyroidism and not a growth hormone problem. Bone age delay was also noted in all four patients, with a mean delay of 3.3 years (Tables 1 and 2). Coeliac screen, insulin-like growth factor 1 and karyotype were also all normal in these patients.

Patient Age at presentation (yrs)  Presenting Symptoms  Pubertal Staging at presentation  Weight SDS at presentation  Height SDS at presentation  Mid-parental height (cm)
1 15  One year history of constipation and short stature  B3P3A2M1  -3.22  -4.99  160
2 13  One year history of constipation, low mood, cold intolerance and poor growth  B3P3A2M2  -0.61  -3.23  168
3 14  Patient had a dizzy spell and collapse at school. A more detailed history revealed she had suffered from cold intolerance, dry skin and hair for the last two years.  B2P2A1M0  -1.93  -4.35  157
4 13  Short stature  B4P4A2M1  -0.19  -3.16  168

Table 1. Demographic, symptoms and examination findings at presentation.

<table>
<thead>
<tr>
<th>Patient</th>
<th>TSH at Presentation (mU/L)</th>
<th>FT4 at Presentation (pmol/L)</th>
<th>TPO Antibodies</th>
<th>Growth Hormone Stimulation Tests using Glucagon</th>
<th>Bone Age Delay (years)</th>
<th>Thyroid Ultrasound</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&gt; 100</td>
<td>Undetectable</td>
<td>Positive</td>
<td>Normal</td>
<td>5</td>
<td>Thyroiditis</td>
</tr>
<tr>
<td>2</td>
<td>&gt; 100</td>
<td>Undetectable</td>
<td>Positive</td>
<td>Normal</td>
<td>2</td>
<td>Thyroiditis</td>
</tr>
<tr>
<td>3</td>
<td>&gt; 100</td>
<td>Undetectable</td>
<td>Positive</td>
<td>Normal</td>
<td>3.8</td>
<td>Thyroiditis</td>
</tr>
<tr>
<td>4</td>
<td>&gt; 100</td>
<td>Undetectable</td>
<td>Positive</td>
<td>Normal</td>
<td>2.5</td>
<td>Thyroiditis</td>
</tr>
</tbody>
</table>

Table 2. Investigations for each patient.

Table 3 shows that the thyroid function tests were normalising in all patients after eight weeks of treatment with thyroxine. The normal range for TSH is 0.4 to 4.0 mU/L and for FT4 it is 9 to 25 pmol/L. The results also show that following thyroxine treatment the patients height SDS improved by 0.645 ± 0.515 (Table 4).
Discussion

Our findings showed that for each patient the hormone stimulation responses were normal and therefore the short stature at presentation was secondary to severe hypothyroidism. This shows the importance of investigating the thyroid function when referred a patient with short stature or reduced height velocity. Other investigations for possible autoimmune hypothyroidism should also include thyroglobulin and thyroid peroxidase antibodies to aid diagnosis. They are thought to be positive in 50% and 90% of patients, respectively [2]. 5% of patients have a negative antibody screen, but diagnosed due to clinical signs or findings on their thyroid ultrasound [2].

Eskes et al. investigated growth hormone deficiency in patients with autoimmune hypothyroidism as it was thought that it was more common than initially thought secondary to autoimmune hypophysitis [15]. This would therefore change medical management for the patients. De Bellis et al. and Manetti et al. both found an association between autoimmune hypothyroidism and growth hormone deficiency [16,17]. Interestingly, Eskes et al.’s study did not show this association and their conclusion was that growth hormone investigations were not indicated [15]. Even though our cohort of patients agreed with this theory, it is reassuring that the growth hormone stimulation tests were normal and no other treatment was required.

It has also been reported that by adding a gonadotropin-releasing hormone (GnRH) analogue to thyroxine treatment, that final height may be improved although results were not conclusive. Teng et al. reviewed thirty three children retrospectively comparing the final height and body mass index in children treated with thyroxine only and those who were treated with both medications [18]. The group of children treated with GnRH analogues were older and shorter than the other group at presentation and the final results showed that both groups had comparable final heights and height deficits [18].

Growth is important for a child’s quality of life and can cause significant anxiety for all those involved [4]. Therefore, optimising catch-up growth is essential for their well-being. There are some reported concerns that final adult height may be reduced following thyroxine treatment due to the sudden increase in bone age progression [10]. Nebesio et al. investigated whether the time to reach euthyroidism was associated with final height outcome and found no significant difference [10]. The authors found no association with additional growth promoting treatments [10]. Our results have shown that following the introduction of thyroxine treatment alone, the height SDS for each peri-pubertal patient improved significantly. Jaruratansirikul et al. followed up patients with Hashimoto’s thyroiditis for six years [19]. The group of patients aged between 9-15.4 years old with biochemical hypothyroidism were found to have normal growth and puberty [19]. Interestingly, the final heights were on average above the mid-parental height [19]. In contrary, an older study showed that hypothyroidism diagnosed in the adolescent period resulted in a reduction in final adult height and was also associated with the delay in diagnosis [20]. These results demonstrate the importance of early detection of hypothyroidism so that treatment can be commenced as a priority.

The stage of puberty has been suggested to affect catch-up growth. de Vries et al. followed up their patients for a total of six years and found that the height SDS improved significantly [11]. This was shown in their entire group, including pubertal patients [11]. This theory was also supported by Jaruratansirikul et al. [19]. In this cohort, our patients have shown improvements in height following immediate treatment. It is important to investigate appropriately, and to include thyroid function tests in patients presenting with growth deceleration and short stature [2].

Conclusion

In conclusion, prompt recognition of hypothyroidism in childhood is essential to initiate treatment early, so that adult height is not compromised.

Acknowledgement

None

Statement of Ethics

Consent obtained from all patients and data was anonymised.

Disclosure Statement

No conflicts of interest to disclose.

Funding

None
Author Contributions

LA – analysed the data, wrote and revised draft.
SMN – supervised the audit, collected data and revised the final draft.

References